BridgeBio Oncology Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2022 | — | $-21.9K | — |
| FY2023 | — | $-115.6M | $250.0K |
| FY2024 | — | $-178.6M | $30.9M |
| FY2025 | — | $411.1M | $373.7M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2022 | — | $-21.9K | — |
| FY2023 | — | $-115.6M | $250.0K |
| FY2024 | — | $-178.6M | $30.9M |
| FY2025 | — | $411.1M | $373.7M |